Summary
The Maharashtra FDA has withdrawn its order to cancel Cipla Pharma's drug sale license after the Bombay High Court criticized its actions. The FDA will now issue a fresh show cause notice to Cipla regarding alleged irregularities in packaging, storage, and recall of certain tablets.